Long-term outcome of randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR).
Dextranomer/hyaluronic acid copolymer
Endoscopic treatment
Polyacrylate-polyalcohol copolymer
Vesicoureteral reflux
Journal
World journal of urology
ISSN: 1433-8726
Titre abrégé: World J Urol
Pays: Germany
ID NLM: 8307716
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
30
01
2023
accepted:
23
07
2023
medline:
23
10
2023
pubmed:
16
8
2023
entrez:
16
8
2023
Statut:
ppublish
Résumé
The aim of our study is to compare long-term outcome of endoscopic treatment of VUR using PPC or Dx/HA. From October 2014 to April 2017 patients with VUR grades from 3 to 5 that needed endoscopic treatment were eligible for this RCT. Patients were randomized in two groups: PPC and Dx/HA. A VCUG was performed at 6 months; if VUR > 3 was still present a second ET was performed. We included for this long-term follow-up study those patients that were successfully treated at short-term follow-up. At 36 months postoperative VCUG was performed to assess outcome. Success was considered if postoperative VUR grade was 0 at 36 months, and there was no ureteral obstruction. In the previous study, 60/73 ureters were successfully treated in 36/44 patients, and then we have analyzed 60 ureters in 36 patients. Three patients were lost in long-term follow-up, and then we analyzed 57 ureters in 33 patients divided. PPC group 18 patients (28 ureters); and Dx/HA group 15 patients (29 ureters). After 3 years of follow-up the VCUG showed a success rate of 26/28 of RU in PPC and 26/29 of DX/HA. Two RU in PPC group had ureteral obstruction, and then the successful rate for PPC group dropped to 24/28. The overall successful rate at long-term was 72.7% of the RU in PPC group and 70.3% in Dx/HA group. PPC and Dx/HA has similar long-term outcome in VUR resolution, but ureteral obstruction could be present at long-term follow-up in PPC group.
Identifiants
pubmed: 37584692
doi: 10.1007/s00345-023-04548-z
pii: 10.1007/s00345-023-04548-z
doi:
Substances chimiques
dextranomer-hyaluronic acid copolymer
0
Hyaluronic Acid
9004-61-9
Types de publication
Randomized Controlled Trial
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
2855-2859Informations de copyright
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.
Références
Kirsch AJ, Perez-Brayfield M, Smith EA, Scherz H (2004) The modified STING procedure to correct vesicoureteral reflux: improved results with submucosal implantation within the intramural ureter. J Urol 171:2413
doi: 10.1097/01.ju.0000127754.79866.7f
pubmed: 15126864
Läckgren G, Wählin N, Skoldenberg E, Stenberg A (2001) Long-term follow-up of children treated with dextranomer/hyaluronic acid copolymer for vesicoureteral reflux. J Urol 166:1887–1892
doi: 10.1016/S0022-5347(05)65713-8
pubmed: 11586255
Ormaechea M, Paladini M, Pisano R, Scagliotti M, Sambuelli R, Lopez S et al (2008) Vantris, a biocompatible, synthetic, non-biodegradable, easy-to-inject bulking substance. Evaluation of local tissular reaction, localized migration and long-distance migration. Arch Esp Urol 61(2):263–268
doi: 10.4321/S0004-06142008000200023
pubmed: 18491745
Ormaechea M, Ruiz E, Denes E et al (2010) New tissue bulking agent (polyacrylate polyalcohol) for treating vesicoureteral reflux: preliminary results in children. J Urol 183:714–717
doi: 10.1016/j.juro.2009.10.047
pubmed: 20022037
Kocherov S, Ulman I, Nikolaev S, Corbetta JP, Rudin Y, Slavkovic A et al (2014) Multicenter survey of endoscopic treatment of vesicoureteral reflux using polyacrylate-polyalcohol bulking copolymer (Vantris). Urology 84(3):689–693
doi: 10.1016/j.urology.2014.04.033
pubmed: 25168553
García-Aparicio L, Blázquez-Gómez E, Martin O, Pérez-Bertólez S, Arboleda J, Soria A et al (2018) Randomized clinical trial between polyacrylate-polyalcohol copolymer (PPC) and dextranomer-hyaluronic acid copolymer (Dx/HA) as bulking agents for endoscopic treatment of primary vesicoureteral reflux (VUR). World J Urol 36:1651–1656
doi: 10.1007/s00345-018-2314-7
pubmed: 29725806
Matouschek E (1981) Treatment of vesicorenal reflux by transurethral teflon-injection (author’s transl). Urol A 20(5):263–264
García-Aparicio L, Blázquez-Gómez E, Vila-Santandreu A, Camacho JA, Vila-Cots J, Ramos M et al (2016) Routine delayed voiding cystourethography after successful endoscopic treatment with Dx/HA of vesicoureteral reflux. Is it necessary? Actas Urol Esp 40(10):635–639
doi: 10.1016/j.acuro.2016.02.007
pubmed: 27161091
Garcia-Aparicio L, Rovira J, Blazquez-Gomez E, Garcia-Garcia L, Gimenez-Llort A, Rodo J et al (2013) Randomized clinical trial comparing endoscopic treatment with dextranomerhyaluronic acid copolymer and Cohen’s ureteral reimplantation for vesicoureteral reflux: long-term results. J Pediatr Urol 9(4):483–487
doi: 10.1016/j.jpurol.2013.03.003
pubmed: 23602843
Warchol S, Krzemien G, Szmigielska A, Bombinski P, Brzewski M, Dudek-Warchol T (2016) Comparison of results of endoscopic correction of vesicoureteral reflux in children using two bulking substances: dextranomer/hyaluronic acid copolymer (Deflux) versus polyacrylate-polyalcohol copolymer (Vantris). J Pediatr Urol 12(4):256.e1–4
doi: 10.1016/j.jpurol.2016.04.006
pubmed: 27593921
Karakus SC, User IR, Kılıc BD (2016) The comparison of dextranomer/hyaluronic acid and polyacrylate-polyalcohol copolymers in endoscopic treatment of vesicoureteral reflux. J Pediatr Surg 1:1496–1500
doi: 10.1016/j.jpedsurg.2016.02.092
Starmer B, McAndrew F, Corbett H (2019) A review of novel STING bulking agents. J Pediatr Urol 15(5):484–490
doi: 10.1016/j.jpurol.2019.08.018
pubmed: 31591047
Chertin B, Mele E, Kocherov S, Zilber S, Gerocarni Nappo S, Capozza N (2018) What are the predictive factors leading to ureteral obstruction following endoscopic correction of VUR in the pediatric population? J Pediatr Urol 14(6):538.e1-538.e7
doi: 10.1016/j.jpurol.2018.04.021
pubmed: 29885870